Elixinol Wellness (EXL) AI Stock Analysis

• Market Cap: $3.60M
• Dividend Yield: N/A
• Average Volume (3M): 186.30K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.97
• Revenue Growth: 36.60%
• EPS Growth: 85.28%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 276,991,420
• 10 Day Avg. Volume: 284,943
• 30 Day Avg. Volume: 186,302
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 0.31
• Enterprise Value/Gross Profit: 0.87
• Enterprise Value/Ebitda: -1.04
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 43 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Elixinol Wellness faces significant challenges with profitability and cash flow management, reflected in a low financial performance score. Technical analysis indicates bearish momentum, and the valuation is unattractive due to negative earnings and lack of dividends. These factors contribute to a low overall stock score.

Elixinol Wellness Business Overview & Revenue Model

Company Description

Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes hemp derived nutraceuticals, cosmetics, and food products under the Elixinol and Hemp Foods Australia brands in the Americas, Europe, and Australia. It offers hemp derived cannabidiol and food products, dietary supplements, topicals, and skincare products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is headquartered in Sydney, Australia.

How the Company Makes Money

Elixinol Wellness makes money primarily through the sale of its hemp-derived products, which include dietary supplements and skincare items. The company's revenue model is centered around direct-to-consumer sales via online platforms, as well as through retail and wholesale distribution channels. Key revenue streams include its branded product lines that cater to different aspects of health and wellness. Additionally, strategic partnerships with retailers and distributors help expand its market presence and drive sales. Significant factors contributing to its earnings include the increasing consumer awareness and demand for natural and plant-based health products, as well as ongoing research and development efforts that lead to innovative product offerings.

Elixinol Wellness Financial Statement Overview

Summary

Elixinol Wellness shows significant revenue growth of 80.88%, but remains unprofitable with negative EBIT and net income margins. The balance sheet indicates low debt levels but declining equity, while cash flow is negative, highlighting the need for improved cash management.

Income Statement

Elixinol Wellness shows a significant improvement in revenue, with a growth rate of 80.88% from 2023 to 2024. However, the company remains unprofitable, with negative EBIT and net income margins, indicating ongoing operational challenges. Gross profit margin is positive but needs improvement to achieve sustained profitability.

Balance Sheet

The company's debt-to-equity ratio remains low at 0.19, indicating a conservative capital structure with manageable debt levels. However, the equity ratio has decreased over time, reflecting a reduction in total assets and equity. Overall, the balance sheet shows stability but requires careful management to improve equity levels.

Cash Flow

The operating cash flow remains negative, indicating the company is not yet generating cash from its operations. Free cash flow is also negative, although there is a slight improvement in free cash flow growth. The company relies on financing to support its cash needs, suggesting a need for improved cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.96M	8.27M	7.05M	9.34M	15.01M
Gross Profit	5.36M	3.27M	-3.27M	-6.25M	-9.58M
EBITDA	-4.06M	-6.81M	-9.28M	-15.51M	-23.36M
Net Income	-1.72M	-7.51M	-10.57M	-17.02M	-104.51M
Balance Sheet
Total Assets	18.45M	11.71M	13.48M	25.33M	42.47M
Cash, Cash Equivalents and Short-Term Investments	1.08M	708.00K	2.86M	12.65M	27.74M
Total Debt	1.94M	1.26M	1.83M	2.65M	2.65M
Total Liabilities	8.42M	5.25M	4.33M	6.25M	6.82M
Stockholders Equity	10.03M	6.46M	9.16M	19.08M	35.65M
Cash Flow
Free Cash Flow	-3.53M	-2.77M	-8.16M	-14.36M	-22.95M
Operating Cash Flow	-3.47M	-2.76M	-8.15M	-14.07M	-22.62M
Investing Cash Flow	-66.00K	-1.04M	-869.00K	172.00K	2.55M
Financing Cash Flow	3.92M	1.61M	-757.00K	-1.16M	27.55M

Elixinol Wellness Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAN	45 Neutral	7.30M	-0.26	0.00%	―	-26.49%	61.72%
EXL	43 Neutral	$3.60M	―	-26.84%	―	36.60%	85.28%
AGH	41 Neutral	16.91M	-1.86	0.00%	―	-47.30%	86.75%
BOD	39 Underperform	4.26M	-15.00	0.00%	―	1.92%	97.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Elixinol Wellness Corporate Events

Elixinol Wellness Limited Announces New Share Offer

Elixinol Wellness Limited, listed on the ASX under the code EXL, has announced a prospectus for an offer of up to 100,000 new shares at $0.10 each, aiming to raise up to $10,000. The prospectus is designed to remove trading restrictions on the sale of shares issued under this offer and previous ones. The company emphasizes that the investment should be considered speculative, with no guarantees on returns or dividends, and advises potential investors to seek professional advice.

Elixinol Wellness to Quote 46.8 Million Securities on ASX

Elixinol Wellness Limited has announced the quotation of 46,800,000 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 12, 2025. This move is part of a previously announced transaction, potentially impacting the company’s market presence and providing stakeholders with increased liquidity and investment opportunities.

Elixinol Wellness Announces Proposed Securities Issue

Elixinol Wellness Limited announced a proposed issue of securities, including options and ordinary fully paid shares, set to be issued on October 24, 2025. This move is part of the company’s strategy to raise capital, potentially impacting its market position and providing opportunities for stakeholders to engage with its growth initiatives.

Elixinol Wellness Announces Proposed Securities Issue

Elixinol Wellness Limited has announced a proposed issue of 46,800,000 ordinary fully paid securities, with the issue date set for September 12, 2025. This move is part of the company’s strategic efforts to enhance its market position and potentially raise capital for future growth initiatives, impacting its operational capabilities and stakeholder interests.

Elixinol Wellness Secures $2.5 Million in Successful Placement

Elixinol Wellness Ltd has successfully raised $2.5 million through a well-supported two-tranche placement, exceeding its initial target of $2 million. The funds will be used to enhance working capital, support inventory growth, streamline operations, and shift towards higher-margin channels to achieve sustained profitability. The company has also appointed Gavin Evans as a strategic advisor to aid in its transformation, following recent acquisitions. This move reflects strong investor confidence in Elixinol’s brands and strategic direction, positioning the company for profitable growth.

Elixinol Wellness Initiates Trading Halt for Pending Financial Announcement

Elixinol Wellness Limited has requested a trading halt on its securities pending an announcement regarding a potential financing or capital raising arrangement. This halt is expected to last until the announcement is made or until normal trading resumes on 8 September 2025, indicating a significant upcoming development that could impact the company’s financial strategy and market position.

Elixinol Wellness Releases H1 2025 Results Presentation

Elixinol Wellness Limited has released its H1 2025 results presentation, which provides a general overview of the company’s current status and future business intentions. The presentation includes forward-looking statements that highlight potential risks and uncertainties, emphasizing the need for investors to exercise caution and not rely solely on the provided information.

Elixinol Wellness Reports Revenue Growth and Strategic Integration Progress

Elixinol Wellness Limited reported a 12.8% year-on-year revenue growth to $7.6 million for the first half of 2025, driven by strong performances from Healthy Chef and Hemp Foods Australia. Despite a loss in adjusted EBITDA due to integration costs, the company achieved margin expansion and improved cash discipline, positioning itself for a stronger second half of the year. The focus remains on e-commerce growth and cost rationalization to sustain momentum into 2026.

Elixinol Wellness Reports Revenue Growth Amidst Rising Losses

Elixinol Wellness Limited reported a 12.8% increase in revenues to $7,642,000 for the half-year ending June 30, 2025, despite a 12.2% increase in losses, totaling $3,093,000. The company’s financial performance reflects ongoing challenges, with no dividends declared and a decrease in net tangible assets, highlighting the need for strategic adjustments to improve profitability and shareholder value.

Elixinol Wellness Refocuses The Healthy Chef Strategy on Australian Market

Elixinol Wellness Ltd has decided to terminate a U.S. distribution agreement for The Healthy Chef products, which was assumed during its acquisition of the brand in 2024. This move allows Elixinol to concentrate on expanding The Healthy Chef’s presence in the Australian market while maintaining the option to explore international opportunities in the future.